RNA Sequencing of AD OM cells exposed to traffic-related air pollutants
Total RNA sequencing of olfactory mucosa (OM) cells derived from individuals diagnosed with Alzheimer's disease exposed to traffic-related ultrafine particles (UFPs) for 24-h and 72-h in submerged cultures. The UFPs used for exposures were: A0, A20 and Euro6. Exposures were compared to the corresponding blank samples.
- 25/07/2024
- 59 samples
- DAC: EGAC00001002527
- Technology: unspecified
The Data Access Committee for Human Olfactory Mucosa Cells (DAC_HOM) at UEF aims to coordinate rapid distribution of the data generated by DAC_HOM to the entire research community with minimal restrictions to accelerate the translation of new knowledge of health and diseases.
Policy for Data Access Requests from the Data Access Committee for Human Olfactory Mucosa Cells (DAC_HOM) at UEF. This document describes policy for data access requests from the Data Access Committee for Human Olfactory Mucosa Cells (DAC_HOM) at UEF. Accessing the UEF controlled access data The datasets are under controlled access. Data access can be applied from the DAC following the instructions of EGA (https://ega-archive.org/access/data-access). The DAC will evaluate the application according to the guidance for DACs by EGA (https://ega-archive.org/submission/data_access_committee) upon the receipt of a data access request. Upon submission of the data access request, you will be asked to provide the following details for DAC: Contact details of the main applicant and any individuals who would need to access the data A short scientific description of the project (ca. 500 words), describing how the datasets will be used or incorporated in the project. A letter of ethics approval for the project if required by the applicant’s home institution or by the country of the applicant’s institution. Application procedure To request access to data from the EGA, you will be asked to complete a basic application form and to agree to the terms and conditions laid out in the Data Access Agreement (DAA). The DAA must be signed by both a representative with institutional authority to sign on behalf of your organization, and the principal investigator responsible for the research project. You will also be requested to list personnel who will be granted access to the data for the purposes of the research project. If your application is successful, you will be asked to designate a “registered user”, under the authority of the principal investigator, who will be issued with a username and password by the EGA to enable access to the database. The DAC will consider applications that include named collaborators, but each institution must sign a separate DAA. Should you wish to share the data with additional collaborators not previously approved, they must make a separate application for access to the data. You agree to use the data only for the approved purpose and project described in your application; use of the data for a new purpose or new or expanded project will require a new application and approval. Acknowledgments Purpose adapted from the Blueprint Data Access Committee Terms of Reference. General principles adapted from the Blueprint Data Access Committee General Principles.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
Study ID | Study Title | Study Type |
---|---|---|
EGAS50000000448 | Transcriptome Analysis |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.
ID | File Type | Size | Located in | |
---|---|---|---|---|
EGAF00008478805 | csv | 5.8 MB | ||
EGAF00008478806 | csv | 5.9 MB | ||
2 Files (11.8 MB) |